Alkermes Strategy After Antidepressant Failures Doubted By Wall Street
This article was originally published in The Pink Sheet Daily
Executive Summary
With a pair of Phase III failures for its major depression disorder candidate ALKS-5461, Alkermes is pinning hopes on a third pivotal trial plus ad hoc analysis of a failed study – a strategy analysts find unlikely to prevail.
You may also be interested in...
Will Alkermes Data Package Support ALKS 5461 Approval?
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak
The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.
And Then There Were 19: NurOwn Adcomm Loses Temporary Voting Member To Last-Minute Recusal
Arizona State University neural transplantation expert Jeffrey Kordower said FDA requested he not participate in the advisory committee because of his relationship with sponsor BrainStorm. Kordower says a 2022 journal article erroneously stated he had an ownership interest in the company.